Targeting tumour blood vessel network is a well-established anti-cancer strategy. However, European scientists showed that antiangiogenic treatments may prompt metastatases and have continued research into this important area.
Renal cell carcinoma (RCC) is the main type of kidney cancer that has consistently increased in incidence. Metastatic RCC has a poor outcome due to resistance to standard chemotherapy and prominent vascularisation pattern. Moreover, RCC represents a paradigm for anti-angiogenic treatment but this often leads to the recurrence of metastases and even the development of new metastatic niches.
Further details: Time to revisit antiangiogenic treatment of cancer